Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study

Lung, Respiratory and Thoracic Cancer
Do you want to read an article? Please log in or register.